Abstract 959P
Background
CTRT is used in eligible locally advanced (LA) SCCHN.
Methods
In a retrospective chart analysis and prospectively maintained database we analyzed data of LA SCCHN (nasopharynx excluded) treated between 2000-2016 and tried to find out prognostic factors for outcome by using appropriate methods. We use weekly cisplatin in dose of 40 mg/m2 weekly for a maximum of 7 weeks, and RT 70 Gy over 7 weeks. Baseline characteristics, treatment delivered, toxicities, response rates, and survival outcome were analysed. For purpose of analysis anyone who received at 5 weeks of cisplatin (200 mg/m2) and 6 weeks of radiation (30#) was considered to have received adequate therapy. Survival outcome was assessed in patients who received treatment. Telephonic contact or verbal autopsy was also carried out to retrieve information. Study was approved by IEC.
Results
1856 patients were considered for CTRT during this period. 1421 records were available. Median age was 51 yrs (14-72). Males were 1297. Primary sites; oropharynx (712), hypopharynx (195), larynx (286), and others (222). 622 had stage 3 and 795 had stage IV disease. 986 had node + disease. ECOG PS was 0 in 119, I in 708, and II in 494 patients. Albumin levels lower than normal was seen in 121 patients and 1157 had normal/higher levels. 1345 received treatment and included for survival analysis, outcome measures, and multi-variate analysis. 1072 (75.4%) patients received at least 5 doses of cisplatin, and 1201 (84.5%) received at least 30 # of radiation. 1071 (75.4%) patients completed treatment. Response was seen in 90.3% (67.8% CR). 330 (24.5%) required hospitalization for various reasons, 499 (37.1%) had treatment breaks. 513 (36.2%) are alive without disease and 635 (44.7%) died (38.9% due to disease and 3.3% due to toxicity). 3.9% developed second primary. Median OS was 54 months. On multi-variate, OS was significantly superior in patients with laryngeal primary, normal albumin, ECOG 0-1, females, stage III, and those who could complete planned treatment.
Conclusions
This large single center series highlights comparable results with CTRT in LA SCCHN. Survival was superior with laryngeal primary, normal albumin, and ECOG 0-1. Toxicity and tolerance was somewhat similar to other reports.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.